Results from this randomized , placebo-controlled study of aripiprazole augmentation to antidepressant therapy ( ADT ) in Japanese patients with major depressive disorder ( MDD ) ( the Aripiprazole Depression Multicenter Efficacy [ ADMIRE ] study ) revealed that aripiprazole augmentation was superior to ADT alone and was well tolerated .